FDA Clears Neurora Tool for Autism Diagnosis
The newly cleared device assists clinicians in diagnosing children by analyzing over 100 distinct biometric markers.
Updated on Oct. 20, 2026 in Autism
Live Poll
Do you trust automated diagnostic tools to improve the accuracy of childhood autism screenings?
The FDA has cleared the Neurora diagnostic tool, developed by Argus Cognitive, Inc., for use in children aged 18 months to 12 years. The system automates behavioral assessments by evaluating facial expressions, voice patterns, and eye gaze.
Why it matters
This technology aims to support the early identification of autism, a condition that the CDC estimates currently affects 1 in 31 children. By providing clinicians with objective biometric data, the tool could help lower the current median age of diagnosis, which remains under 4 years old.
A study published earlier in 2026 demonstrated that the tool identifies autism in nearly 78% of cases using more than 100 biometrics. The device is cleared for use in children ranging from 18 months to 12 years old.
The players
FDA
The Food and Drug Administration is the federal agency responsible for protecting public health by ensuring the safety and efficacy of medical devices.
Argus Cognitive, Inc.
Argus Cognitive, Inc. is the medical technology company that developed the Neurora diagnostic device.
CDC
The Centers for Disease Control and Prevention is the national public health agency that tracks the prevalence of health conditions across the United States.
The details
Clinicians perform behavioral assessments, uploading video and audio files to the Neurora portal for automated analysis. The platform then compares these behavioral metrics against a reference set of data from children both with and without autism to generate insights.
Timeline
The FDA cleared the Neurora tool in October 2026.
A study regarding the diagnostic accuracy of the tool was published earlier in 2026.
The Big Picture
The FDA clearance of the EarliPoint Evaluation for ASD established a regulatory pathway for automated autism diagnostics, and the clearance of Neurora follows the pattern set by it.
Parents and caregivers may see this tool integrated into routine behavioral evaluations, potentially resulting in faster diagnostic outcomes for children. Clinicians can now utilize the platform to support their assessments with objective biometric evidence.
The takeaway
This technology represents a move toward incorporating artificial intelligence into developmental healthcare to standardize clinical assessments. Families should consult with their pediatricians to understand if such tools are available for use in their child's evaluation process.
Further reading
For more information on the diagnostic landscape, visit Autism.
Live Poll
Do you trust automated diagnostic tools to improve the accuracy of childhood autism screenings?
